Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study
Vesal Yaghoobi(Yale University), David L. Rimm(Yale University), Thazin Nwe Aung(Yale University), Lajos Pusztai(Yale University), Anup Sharma(Johns Hopkins University), Tess A. O’Meara(Yale University), Aileen I. Fernandez(Yale University), Sanam Yaghoubi(National Cancer Institute), Kim Blenman(Medical University of South Carolina), Myrto Moutafi(University General Hospital Attikon), Saba Shafi(Ministry of Education of the People's Republic of China), Ioannis Vathiotis(Yale University), Vasiliki Pelekanou(Bayer (United States)), Eiman Ibrahim(Yale University)
Cited by 8
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k